Please use this identifier to cite or link to this item: https://doi.org/10.3389/fphar.2021.684907
DC FieldValue
dc.titlePharmacogenomics Implementation Training Improves Self-Efficacy and Competency to Drive Adoption in Clinical Practice
dc.contributor.authorAdesta, Fadhli
dc.contributor.authorMahendra, Caroline
dc.contributor.authorJunusmin, Kathleen Irena
dc.contributor.authorRajah, Arya Melissa Selva
dc.contributor.authorGoh, Sharon
dc.contributor.authorSani, Levana
dc.contributor.authorChan, Alexandre
dc.contributor.authorIrwanto, Astrid
dc.date.accessioned2022-10-26T09:10:57Z
dc.date.available2022-10-26T09:10:57Z
dc.date.issued2021-06-28
dc.identifier.citationAdesta, Fadhli, Mahendra, Caroline, Junusmin, Kathleen Irena, Rajah, Arya Melissa Selva, Goh, Sharon, Sani, Levana, Chan, Alexandre, Irwanto, Astrid (2021-06-28). Pharmacogenomics Implementation Training Improves Self-Efficacy and Competency to Drive Adoption in Clinical Practice. Frontiers in Pharmacology 12 : 684907. ScholarBank@NUS Repository. https://doi.org/10.3389/fphar.2021.684907
dc.identifier.issn1663-9812
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/233694
dc.description.abstractBackground: Administration of pharmacogenomics (PGx) testing in clinical practice has been suboptimal, presumably due to lack of PGx education. Here, we aim to evaluate the standpoint of PGx testing among a diverse group of healthcare professionals (HCPs) through conducting surveys before and after training. Materials and Methods: Training modules were designed to cover three key learning objectives and deployed in five sections. A pre- and post-training survey questionnaire was used to evaluate participants’ self-assessments on employing PGx in clinical practice. Results and Conclusion: Out of all enrollments, 102 survey responses were collected. Overall, respondents agree on the benefits of PGx testing, but have inadequate self-efficacy and competency in utilizing PGx data. Our results show that a 90 min long training significantly improves these, and could lead to greater anticipation of PGx adoption. © Copyright © 2021 Adesta, Mahendra, Junusmin, Rajah, Goh, Sani, Chan and Irwanto.
dc.publisherFrontiers Media S.A.
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2021
dc.subjecteducation
dc.subjecthealthcare professionals
dc.subjectimplementation training
dc.subjectpharmacogenomics
dc.subjectprogram evaluation
dc.typeArticle
dc.contributor.departmentPHARMACY
dc.description.doi10.3389/fphar.2021.684907
dc.description.sourcetitleFrontiers in Pharmacology
dc.description.volume12
dc.description.page684907
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3389_fphar_2021_684907.pdf3.48 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons